Efficacy of Upadacitinib in refractory Polyarteritis Nodosa: a case report

Polyarteritis nodosa (PAN) is systemic vasculitis, typically treated with a combination of glucocorticoids and immunosuppressants. Changing the immunosuppressant is recommended if remission cannot be achieved with these treatments. However, there is a lack of further treatment options for patients who are unresponsive to all immunosuppressants. We report a 44-year-old Japanese man with refractory PAN who was unresponsive to various immunosuppressants (including tocilizumab). Upadacitinib treatment led to relatively rapid symptom improvement, allowing for tapering and eventual discontinuation of immunosuppressants, including prednisolone. During his 1-year follow-up, no relapse or side effects were noted. This case suggests that Janus kinase inhibitors may provide a breakthrough for patients with refractory PAN.

Authors

Institutions

Publication Details

Journal
Oxford Medical Case Reports
Published
2025-02-01
DOI
https://doi.org/10.1093/omcr/omae199
Citations
2
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
3.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of Upadacitinib in refractory Polyarteritis Nodosa: a case report

Akihiko Nakabayashi, Shiro Ohshima, Maiko Yoshimura, Hyota Takamatsu et al.
2 citations
Oxford Medical Case Reports
Vasculitis and related conditions
3.04
article

Efficacy of Upadacitinib in refractory Polyarteritis Nodosa: a case report

Akihiko Nakabayashi, Shiro Ohshima, Maiko Yoshimura, Hyota Takamatsu, Daekeun Kim, Erika Iguchi, Yanakawee Siripongvutikorn, Akira Nishigaichi
article en
2 citations

Abstract

Polyarteritis nodosa (PAN) is systemic vasculitis, typically treated with a combination of glucocorticoids and immunosuppressants. Changing the immunosuppressant is recommended if remission cannot be achieved with these treatments. However, there is a lack of further treatment options for patients who are unresponsive to all immunosuppressants. We report a 44-year-old Japanese man with refractory PAN who was unresponsive to various immunosuppressants (including tocilizumab). Upadacitinib treatment led to relatively rapid symptom improvement, allowing for tapering and eventual discontinuation of immunosuppressants, including prednisolone. During his 1-year follow-up, no relapse or side effects were noted. This case suggests that Janus kinase inhibitors may provide a breakthrough for patients with refractory PAN.

Oxford Medical Case ReportsVol. 2025(2)
Osaka Minami Medical Center (JP)
Good health and well-being
Openalex Percentile: Top 11%
Vasculitis and related conditions
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy of Upadacitinib in refractory Polyarteritis Nodosa: a case report — Akihiko Nakabayashi, Shiro Ohshima, et al. · Oxford Medical Case Reports (2025) | TGRS Research Map | TGRS